From the Research
For an adolescent patient weighing 86.15 kg with psoriatic arthritis, the recommended guselkumab dosing is 100 mg administered as a subcutaneous injection at weeks 0 and 4, followed by maintenance dosing of 100 mg every 8 weeks thereafter. This dosing regimen is based on the most recent and highest quality study available, which demonstrates the efficacy and safety of guselkumab in patients with psoriatic arthritis 1. The medication should be administered by a healthcare professional or, after proper training, can be self-administered or given by a caregiver. Each dose comes as a single-use 100 mg/1 mL prefilled syringe or autoinjector that should be stored in the refrigerator (2-8°C) and protected from light. Before injection, allow the syringe to reach room temperature for 30 minutes. Common injection sites include the front of thighs, lower abdomen, or outer upper arms. Guselkumab works by selectively targeting the IL-23 pathway, which plays a key role in the inflammatory process of psoriatic arthritis. Regular monitoring for infection, tuberculosis reactivation, and injection site reactions is recommended throughout treatment. Key points to consider when administering guselkumab include:
- Fixed dosing: 100 mg every 8 weeks after initial doses at weeks 0 and 4
- No weight-based adjustment needed for patients over 50 kg
- Administration by healthcare professional or trained individual
- Storage and handling requirements
- Common injection sites
- Mechanism of action: IL-23 pathway inhibition
- Monitoring for potential adverse effects. It's worth noting that while other studies have evaluated the efficacy of guselkumab in psoriatic arthritis, the most recent and highest quality study 1 provides the best evidence for dosing recommendations. Additionally, studies such as 2 and 3 provide further support for the use of guselkumab in psoriatic arthritis, but the dosing recommendations remain consistent with those outlined in the most recent study 1. Overall, the recommended dosing regimen for guselkumab in an adolescent patient weighing 86.15 kg with psoriatic arthritis is 100 mg every 8 weeks after initial doses at weeks 0 and 4.